Statements (61)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
vaccine
|
| gptkbp:antiSubmarineWarfare |
addressed in trials
|
| gptkbp:approves |
WHO
|
| gptkbp:brand |
gptkb:Vaxzevria
|
| gptkbp:caseOutcome |
monitored post-authorization
|
| gptkbp:clinicalTrials |
over 30,000
Phase III trials prevent COVID-19 infection |
| gptkbp:community |
significant
|
| gptkbp:communityImpact |
aims to reduce pandemic effects
|
| gptkbp:contraindication |
thrombosis with thrombocytopenia syndrome
mild to moderate side effects |
| gptkbp:developedBy |
gptkb:AstraZeneca
|
| gptkbp:diseaseResistance |
conducted in various populations
critical for public confidence integrated into national vaccination programs |
| gptkbp:distribution |
global
|
| gptkbp:dosageForm |
two doses
|
| gptkbp:emergencyServices |
multiple countries
|
| gptkbp:endOfProduction |
under investigation
|
| gptkbp:evaluates |
approximately 76%
|
| gptkbp:expansion |
recommended after initial vaccination
|
| gptkbp:firstDescribedBy |
recommended 8 to 12 weeks apart
|
| gptkbp:historicalResearch |
international research networks
|
| https://www.w3.org/2000/01/rdf-schema#label |
AstraZeneca vaccine
|
| gptkbp:isSubjectTo |
collected from millions of doses administered
|
| gptkbp:notable_event |
required before administration
|
| gptkbp:notable_player |
varies by country
mixed responses public and private sectors collaboration with universities conditional marketing authorization non-replicating viral vector stable at refrigerator temperatures against variants of concern history of severe allergic reactions ongoing for variants important for public trust advancements in vaccine technology addressed through education campaigns adverse event reporting systems collaboration with global health organizations equitable access efforts issued by health organizations reduces severe disease and hospitalization reduces transmission of virus started in early 2021 |
| gptkbp:produces |
multiple countries
|
| gptkbp:providesGuidelinesFor |
developed by health agencies
|
| gptkbp:providesSupportFor |
gptkb:COVAX_initiative
|
| gptkbp:reproduction |
available through health authorities
|
| gptkbp:researchContribution |
efforts to reach low-income countries
|
| gptkbp:safetyFeatures |
ongoing studies
|
| gptkbp:shoots |
two-dose regimen
|
| gptkbp:storage |
2 to 8 degrees Celsius
|
| gptkbp:takesPlaceIn |
complex_logistics_involved
|
| gptkbp:targets |
gptkb:COVID-19
|
| gptkbp:teamAchievements |
aims to achieve herd immunity
|
| gptkbp:triggerType |
uses a modified chimpanzee adenovirus
|
| gptkbp:type |
viral vector vaccine
|
| gptkbp:updates |
regularly published by manufacturers
|